US FDA slow in debarring clinical investigators convicted of wrongdoings
This article was originally published in SRA
The US Food and Drug Administration fails to debar quickly enough clinical investigators convicted of contravening medical product regulations from engaging in research, according to a Government Accountability Office report1.
You may also be interested in...
Three companies are set to learn this week whether the European Medicines Agency will fast track its review of their soon-to-be-filed EU marketing applications.
Janssen and AstraZeneca are among a raft of companies that might this week find out whether the European Medicines Agency will recommend approval of their products for expanded therapeutic indications.
Oral explanation meetings are due to take place this week for drug sponsors who have a final chance to address questions and concerns the European Medicines Agency has about their marketing applications.